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Paraneoplastic Neuromyelitis Optica Associated 
with Lung Adenocarcinoma in a Young Woman
Dear Editor, 
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disor-
der of the central nervous system that preferentially affects the optic nerve, spinal cord, and 
area postrema.1 The serum anti-aquaporin-4 antibody (anti-AQP-4 antibody) is specific for 
NMOSD. There are only a few reports of NMOSD presenting in the context of paraneoplastic 
neurological syndromes. Here we report a young woman who developed recurrent NMOSD 
in the setting of a lung adenocarcinoma. 
A previously healthy 37-year-old woman presented with a palpable mass on the right side 
of the neck. The patient was diagnosed with metastatic adenocarcinoma after a biopsy of 
the mass, which was in a neck lymph node. Chest computed tomography and whole-body 
positron-emission tomography/computed tomography (PET-CT) revealed that the main 
mass was in her lung and that multiple metastases were present, classifying it as stage 4 (Fig. 
1A). An EGFR mutation (deletion of exon 19) was also detected in the biopsied tissue. 
During the diagnostic workup she developed progressive weakness of all extremities. 
When she visited our clinic, a neurological examination revealed weakness of Medical Re-
search Council grade 3 to 4 in the upper extremities and grade 1 in the lower extremities, 
with hypoesthesia below the neck. She did not have an oral or genital ulcer, sicca syndrome, 
abnormal rash, or other manifestations implicating autoimmune disorders. Spine magnetic 
resonance imaging (MRI) showed a T2-weighted hyperintense lesion from level C2 to level 
T7 with gadolinium enhancement (Fig. 1B and C). Brain MRI revealed no abnormality. Ce-
rebrospinal fluid analysis showed pleocytosis (60 cells/µL, 98% mononuclear cells) and an 
elevated protein level (138.2 mg/dL) without malignant cells or an oligoclonal band. Anti-
AQP-4 antibody (indirect immunofluorescence test; Euroimmun, Lübeck, Germany) was de-
tected in the serum. She was negative for antinuclear antibody. Based on these results she was 
diagnosed with NMOSD and was treated with a daily intravenous infusion of 1 g of methyl-
prednisolone for 5 days, followed by a tapering course of oral prednisolone from an initial 45 
mg daily [1 mg/kg body weight (47 kg)] to 10 mg daily at 3 months after the onset of myelitis. 
The lung adenocarcinoma was treated concurrently with gefitinib. 
Three months after presenting with myelitis she experienced a painful visual disturbance 
in the left eye. An examination revealed bilateral papilledema and a visual field defect of the 
lower quadrant in the left eye. The visual acuity of her left eye was finger counting at 50 cm. 
Orbit MRI revealed an enlarged bilateral optic nerve with segmental enhancement of the left 
optic nerve (Fig. 1D and E). Optic neuritis was diagnosed. At this time her cancer was stable 
with gefitinib treatment. She was treated with another steroid pulse therapy (daily intrave-
nous infusion of 1 g of methylprednisolone for 5 days), followed by a tapering course of oral 
prednisolone as for the previous myelitis. In addition, azathioprine was added at 150 mg daily 
[2.5 mg/kg body weight (60 kg)]. At 8 months after presenting with optic neuritis she was tak-
ing 5 mg of prednisolone and 150 mg of azathioprine daily. At 1 month after presenting with 
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optic neuritis her visual acuity recovered to 0.7. At the latest fol-
low up, which was performed 8 months after presenting with 
optic neuritis, she remained relapse-free with an EDSS score 
of 3.5.
Immunohistochemistry of formalin-fixed paraffin-embed-
ded slides of the patient’s neck lymph nodes showed positivity 
for membranous AQP-4 immunoreactivity in the cluster of 
the metastatic carcinoma [anti-AQP4 antibody (A5971, Sig-
ma-Aldrich, St. Louis, MO, USA)] (Fig. 1F).
Paraneoplastic NMOSD has been reported recently,2 with 
some studies showing AQP-4 expression in the actual tumor 
cells.3,4 AQP-4 may have role in tumor progression, invasion, 
and metastasis.5 However, the pathophysiology underlying 
paraneoplastic NMOSD remains to be elucidated. 
Combined treatment of anticancer therapy and an immu-
nosuppressive agent usually results in paraneoplastic NMOSD 
that is episodic.3,6 One recurrent case occurred under the cir-
cumstance of cancer relapse.7 However, in our patient the 
NMOSD recurred in spite of combined treatment and rela-
tively stable cancer. Therefore, the clinician should keep the 
possibility of recurrence in mind, and might consider additive 
immunosuppressive treatment upon the recurrence of para-
neoplastic NMOSD. 
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Fig. 1. Findings of imaging and immunohistochemistry studies. A: Positron-emission tomography/computed tomography showed increased FDG up-
take in the lung and multiple lymph-node metastases. B: Sagittal T2-weighted image of the spine revealing a hyperintense lesion from level C2 to level 
T7. C: Sagittal T1-weighted image of the spine after infusing gadolinium showing multifocal enhancement. D: Coronal T2-weighted image of the orbit 
revealing bilateral optic nerve enlargement. E: Sagittal T1-weighted image of the spine after infusing gadolinium showing segmental enhancement of 
the left optic nerve (arrow). F: Immunohistochemistry of the patient’s neck lymph nodes showed positive membranous anti-aquaporin-4 immunore-
activity (open arrows) (×400).
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